RenalGuard Solutions late last week released results from a feasibility study of its RenalGuard-guided diuretic therapy intended to improve fluid management in patients with acute decompensated heart failure and alleviate related symptoms.
Results from the study were presented at the European Society of Cardiology’s Heart Failure 2018 conference in Vienna, the Milford, Mass.-based company said.
The company said its RenalGuard-guided diuretic therapy is intended to allow for the use of an increased dose of diuretics without increasing the risk of diuretic resistant to allow for the safe and effective removal of excess fluids from ADHF patients, alongside alleviating certain symptoms.
A total of nine patients were evaluated in the feasibility study, with patients undergoing 24 hours of standard diuretic therapy with intravenous furosemide followed by 24 hours of diuretics in conjunction with its guided diuretic therapy.
Results indicated that patients in the experiment were able to achieve a safe rate of fluid loss through the induction of high urine rates, and that intravascular volume was maintained during treatment, the company said.
Study data also showed a significant improvement in breathing patterns and diuretic efficiency among RenalGuard patients, touting the creation of more than 2.5 times the amount of urine produced. The average change in estimated kidney function at 30 days post-treatment was reported as 8%, while three patients showed an increase of more than 25%, RenalGuard said.
“We are thrilled to reveal late-breaking data that demonstrates a promising step towards a new therapy for patients suffering from Acute Decompensated Heart Failure. RenalGuard-Guided Diuretic Therapy has the potential to establish a new front-line standard of care for heart failure patients, allowing physicians to maximize fluid removal while protecting patients from the potential negative impact of excessive fluid loss,” CEO Jim Dillon said in a press release.
In January, RenalGuard released results from a first-in-man feasibility study of its RenalGuard System designed to manage fluids during diuretic therapy to treat congestive heart failure in patients suffering from fluid overload.